Abstract:The spread of multidrug-resistant (MDR) Gram-negative bacteria (GNB) has led to serious public health problems worldwide. Colistin, as a "last resort" for the treatment of MDR bacterial infections, has been used significantly in recent years and has led to the continuous emergence of colistin-resistant strains. In this study, we aimed to investigate the synergistic effect on the antimicrobial and antibiofilm activities of a colistin/furanone C-30 combination against colistin-resistant GNB in vitro and in vivo. According to antimicrobial resistance profiles, most of the colistin-resistant strains we collected showed MDR phenotypes. The checkerboard method and time-kill curve showed that the combination with furanone C-30 increases the antibacterial activity of colistin significantly. In addition, the furanone C-30/colistin combination can not only inhibit the formation of bacterial biofilm but also has a better eradication effect on preformed mature biofilms. The result of scanning electron microscopy (SEM) demonstrated that the furanone C-30/colistin combination led to a significant reduction in the number of cells in biofilms. Furthermore, furanone C-30 at 50 mg/ml did not cause any additional toxicity to RAW264.7 cells according to a cytotoxicity assay. In in vivo infection experiments, the furanone C-30/colistin combination increased the survival rate of infected Galleria mellonella larvae as well as decreased the microbial load in a mouse thigh infection model. The synergistic effect of the furanone C-30/colistin combination against colistin-resistant GNB is encouraging, and this work may shed light on a new therapeutic approach to combat colistin-resistant pathogens. IMPORTANCE Colistin is among the few antibiotics effective against multidrug-resistant Gram-negative bacteria (GNB) clinical isolates. However, colistin-resistant GNB strains have emerged in recent years. Therefore, the combination of colistin and nonantibacterial drugs has attracted much attention. In this study, the furanone C-30/colistin combination showed good antibacterial and antibiofilm activity in vitro and in vivo. In addition, increased membrane permeability leads to the synergistic effect of the furanone C-30/colistin combination. Because of the low cytotoxicity of furanone C-30, this combination has good application prospects in clinical anti-infective therapy. This finding might shed light on the discovery of combination therapy for infections caused by colistin-resistant GNB pathogens.

Activity of Tigecycline or Colistin in Combination with Zidovudine against Escherichia coli Harboring tet (X) and mcr-1

Colistin Combined with Tigecycline: A Promising Alternative Strategy to Combat Escherichia Coli Harboring Blandm–5 and Mcr-1

A method for screening tigecycline-resistant gene tet(X) from human gut

MALDI-TOF MS Combined with AUC Method for Tigecycline Susceptibility Testing in Escherichia Coli

In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii

Combining Colistin with Furanone C-30 Rescues Colistin Resistance of Gram-Negative Bacteria in Vitro and in Vivo

In Vitro / Vivo Activity of Potential MCR-1 Inhibitor in Combination With Colistin Againsts mcr -1-Positive Klebsiella pneumonia .

Novel partners with colistin to increase its in vivo therapeutic effectiveness and prevent the occurrence of colistin resistance in NDM- and MCR-co-producing Escherichia coli in a murine infection model

In Vitro and in Vivo Synergistic Effects of Tigecycline Combined with Aminoglycosides on Carbapenem-Resistant Klebsiella Pneumoniae.

[Synergistic Effect of Β-Thujaplicin and Tigecycline Against Tet(x4)-Positive Escherichia Coli in Vitro].

Co-production of Tet(X) and MCR-1, Two Resistance Enzymes by A Single Plasmid.

In vitro and in vivo comparison of eravacycline- and tigecycline-based combination therapies for tigecycline-resistant Acinetobacter baumannii

Increased Activity of Colistin in Combination with Amikacin Against Escherichia Coli Co-Producing NDM-5 and MCR-1.

Proteomics Study of the Synergistic Killing of Tigecycline in Combination with Aminoglycosides Against Carbapenem-Resistant Klebsiella Pneumoniae.

Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli

Activities of Colistin- and Minocycline-Based Combinations Against Extensive Drug Resistant Acinetobacter Baumannii Isolates from Intensive Care Unit Patients

Mechanism of synergistic action of colistin with resveratrol and baicalin against mcr-1-positive Escherichia coli

Conversion to colistin susceptibility by tigecycline exposure in colistin-resistant Klebsiella pneumoniae and its implications to combination therapy

Synergistic Activity of Colistin Combined With Auranofin Against Colistin-Resistant Gram-Negative Bacteria

Restoring Colistin Sensitivity in Multidrug-Resistant Pathogenic E. coli Using Cinacalcet Hydrochloride

In Vitro and in Vivo Efficacy of Cefiderocol Plus Tigecycline, Colistin, or Meropenem Against Carbapenem-Resistant Acinetobacter Baumannii